How much funding has Brano raised?

Brano has raised $6.8M in total funding, most recently a Seed round.

Who are Brano's investors?

Brano's investors include Trinity Innovation Bioventure Singapore, Enterprise Singapore Seeds Capital.

Where is Brano headquartered?

Brano is headquartered in Singapore, Singapore.

What industry is Brano in?

Brano operates in Biotech, Healthcare.

Brano

Advancing novel therapies for heart failure

Singapore, Singapore · Founded 2026 · $6.8M raised

Biotech

Healthcare

Headquarters: Singapore
Employees: 1–10
Founded: 2026
Business Model: B2B

Website: branotherapeutics.com
Total Funding: $6.8M
Last Round: $6.8M SeedMay 2026
Rounds: 1

About

Brano Therapeutics is a biotechnology spin-off from Duke-NUS Medical School in Singapore, focused on developing novel treatments for heart failure, including Heart Failure with preserved Ejection Fraction (HFpEF). The company is built on research identifying a distinct metabolic abnormality in failing hearts — where the heart becomes less efficient at processing key nutrients — and is developing compounds that restore metabolic regulation to reduce heart stiffness and improve cardiac function. Backed by Trinity Innovation Bioventure Singapore (TIBS), SEEDS (SG Growth Capital), SGInnovate, and Duke-NUS' LIVE Ventures, Brano aims to advance its lead program into clinical trials by 2029.

Summary

Brano is a Biotech company based in Singapore, Singapore, founded in 2026. It has raised $6.8M in total across 1 round, most recently a $6.8M Seed round in May 2026. Investors include Trinity Innovation Bioventure Singapore and Enterprise Singapore Seeds Capital.